Genetic Variation in Organic Cation Transport 1 (OCT1) and Its Significance for Morphine Pharmacokinetics

PHASE1CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

February 7, 2020

Study Completion Date

February 7, 2020

Conditions
Organic Cation Transporter 1Morphine
Interventions
DRUG

Morphine

The study was designed as an open, non-controlled drug trial, with scientists and participants blinded to the patients OCT1 status. Morphine will be given as a single dosis (0,15 mg/kg) at the end of the Surgery and later as boluses of 0,04mg/kg administrated by patient-controlled analgesia, (PCA). Blood samples with drug concentrations will be used to determine a difference in morphine AUC due to the patients OCT1 status. Questionnaire answers will be used to determine the effect of morphine due to the patients OCT1 status

Trial Locations (2)

5000

Odense Universitetshospital, Odense

7100

Sydvestjysk Sygehus, Esbjerg

All Listed Sponsors
collaborator

Danish Council for Independent Research

OTHER

collaborator

The Faculty of Health Sciences SDU

UNKNOWN

collaborator

Region of Southern Denmark

OTHER

lead

University of Southern Denmark

OTHER

NCT03425084 - Genetic Variation in Organic Cation Transport 1 (OCT1) and Its Significance for Morphine Pharmacokinetics | Biotech Hunter | Biotech Hunter